These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 23747310)
1. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310 [TBL] [Abstract][Full Text] [Related]
2. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology. Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128 [TBL] [Abstract][Full Text] [Related]
3. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Gomez A; Ferrer I Acta Neuropathol; 2010 Aug; 120(2):155-67. PubMed ID: 20232069 [TBL] [Abstract][Full Text] [Related]
4. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749 [TBL] [Abstract][Full Text] [Related]
6. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons. Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152 [TBL] [Abstract][Full Text] [Related]
7. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. Gaig C; Martí MJ; Ezquerra M; Rey MJ; Cardozo A; Tolosa E J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):626-8. PubMed ID: 17210620 [TBL] [Abstract][Full Text] [Related]
8. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons. Henderson MX; Peng C; Trojanowski JQ; Lee VMY Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356 [TBL] [Abstract][Full Text] [Related]
9. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653 [TBL] [Abstract][Full Text] [Related]
10. Biochemical and pathological characterization of Lrrk2. Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584 [TBL] [Abstract][Full Text] [Related]
11. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease. Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063 [TBL] [Abstract][Full Text] [Related]
12. Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A; Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166 [TBL] [Abstract][Full Text] [Related]
13. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075 [TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease. Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655 [TBL] [Abstract][Full Text] [Related]
15. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743 [TBL] [Abstract][Full Text] [Related]
16. Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology. Jackson LM; Woodruff BK; Tremblay C; Shill HA; Beach TG; Serrano GE; Adler CH Mov Disord Clin Pract; 2024 Jul; 11(7):874-878. PubMed ID: 38757351 [TBL] [Abstract][Full Text] [Related]
17. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD. Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633 [TBL] [Abstract][Full Text] [Related]
18. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT. Ling H; Kara E; Bandopadhyay R; Hardy J; Holton J; Xiromerisiou G; Lees A; Houlden H; Revesz T Neurobiol Aging; 2013 Dec; 34(12):2889.e5-9. PubMed ID: 23664753 [TBL] [Abstract][Full Text] [Related]
19. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models. Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827 [TBL] [Abstract][Full Text] [Related]